These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 28447581)

  • 1. Effect of cisplatin-based neoadjuvant chemotherapy on survival in patients with bladder cancer: a meta-analysis.
    Li G; Niu HM; Wu HT; Lei BY; Wang XH; Guo XB; Feng SL
    Clin Invest Med; 2017 Apr; 40(2):E81-E94. PubMed ID: 28447581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Meta-analysis of neoadjuvant chemotherapy compared to radical cystectomy alone in improving overall survival of muscle-invasive bladder cancer patients.
    Hamid ARAH; Ridwan FR; Parikesit D; Widia F; Mochtar CA; Umbas R
    BMC Urol; 2020 Oct; 20(1):158. PubMed ID: 33054762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant and adjuvant treatments in muscle-invasive bladder cancer: Where are we?
    Osanto S; Álvarez Gómez de Segura C
    Arch Esp Urol; 2020 Dec; 73(10):971-985. PubMed ID: 33269716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Systematic Review and Two-Step Meta-Analysis.
    Yin M; Joshi M; Meijer RP; Glantz M; Holder S; Harvey HA; Kaag M; Fransen van de Putte EE; Horenblas S; Drabick JJ
    Oncologist; 2016 Jun; 21(6):708-15. PubMed ID: 27053504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Downstaging and Survival Associated with Neoadjuvant Immunotherapy Before Radical Cystectomy for Muscle-invasive Bladder Cancer.
    Grassauer J; Schmidt J; Cowan A; Gilbert SM; Chakiryan NH
    Eur Urol Oncol; 2024 Feb; 7(1):139-146. PubMed ID: 37453853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncologic Outcomes for Patients with Residual Cancer at Cystectomy Following Neoadjuvant Chemotherapy: A Pathologic Stage-matched Analysis.
    Bhindi B; Frank I; Mason RJ; Tarrell RF; Thapa P; Cheville JC; Costello BA; Pagliaro LC; Karnes RJ; Thompson RH; Tollefson MK; Boorjian SA
    Eur Urol; 2017 Nov; 72(5):660-664. PubMed ID: 28545841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High aurora kinase expression identifies patients with muscle-invasive bladder cancer who have poor survival after neoadjuvant chemotherapy.
    Burgess EF; Livasy C; Trufan S; Hartman A; Guerreri R; Naso C; Clark PE; Grigg C; Symanowski J; Raghavan D
    Urol Oncol; 2019 Dec; 37(12):900-906. PubMed ID: 31597600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Defects in DNA Repair Genes Confer Improved Long-term Survival after Cisplatin-based Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer.
    Miron B; Hoffman-Censits JH; Anari F; O'Neill J; Geynisman DM; Zibelman MR; Kutikov A; Viterbo R; Greenberg RE; Chen D; Lallas CD; Trabulsi EJ; Alpaugh RK; Dulaimi E; Golemis EA; Uzzo R; Ross EA; Plimack ER
    Eur Urol Oncol; 2020 Aug; 3(4):544-547. PubMed ID: 32165095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder.
    Szabados B; Kockx M; Assaf ZJ; van Dam PJ; Rodriguez-Vida A; Duran I; Crabb SJ; Van Der Heijden MS; Pous AF; Gravis G; Herranz UA; Protheroe A; Ravaud A; Maillet D; Mendez MJ; Suarez C; Linch M; Prendergast A; Tyson C; Stanoeva D; Daelemans S; Rombouts M; Mariathasan S; Tea JS; Mousa K; Sharma S; Aleshin A; Banchereau R; Castellano D; Powles T
    Eur Urol; 2022 Aug; 82(2):212-222. PubMed ID: 35577646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) as neoadjuvant chemotherapy for patients with muscle-invasive transitional cell carcinoma of the bladder.
    Blick C; Hall P; Pwint T; Al-Terkait F; Crew J; Powles T; Macaulay V; Munro N; Douglas D; Kilbey N; Protheroe A; Chester JD
    Cancer; 2012 Aug; 118(16):3920-7. PubMed ID: 22614698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathological downstaging following radical cystectomy for muscle-invasive bladder cancer: Survival outcomes in the setting of neoadjuvant chemotherapy versus transurethral resection only.
    Cajipe M; Wang H; Elshabrawy A; Kaushik D; Liss M; Svatek R; Wu S; Chowdhury WH; Ramamurthy C; Mansour AM
    Urol Oncol; 2020 Apr; 38(4):231-239. PubMed ID: 31956078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of adjuvant cisplatin-based chemotherapy following radical cystectomy in locally advanced muscle-invasive bladder cancer: Systematic review and meta-analysis of randomized trials.
    Kim DK; Lee JY; Jung JH; Hah YS; Cho KS
    Investig Clin Urol; 2019 Mar; 60(2):64-74. PubMed ID: 30838338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistent muscle-invasive bladder cancer after neoadjuvant chemotherapy: an analysis of Surveillance, Epidemiology and End Results-Medicare data.
    Lane G; Risk M; Fan Y; Krishna S; Konety B
    BJU Int; 2019 May; 123(5):818-825. PubMed ID: 30126053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists.
    Lancet; 1999 Aug; 354(9178):533-40. PubMed ID: 10470696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of pathologic complete response with survival after neoadjuvant chemotherapy in bladder cancer treated with cystectomy: a meta-analysis.
    Petrelli F; Coinu A; Cabiddu M; Ghilardi M; Vavassori I; Barni S
    Eur Urol; 2014 Feb; 65(2):350-7. PubMed ID: 23849998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Gender on Chemotherapeutic Response and Oncologic Outcomes in Patients Treated With Radical Cystectomy and Perioperative Chemotherapy for Bladder Cancer: A Systematic Review and Meta-Analysis.
    Kimura S; Iwata T; Abufaraj M; Janisch F; D'Andrea D; Moschini M; Al-Rawashdeh B; Fajkovic H; Seebacher V; Egawa S; Shariat SF
    Clin Genitourin Cancer; 2020 Apr; 18(2):78-87. PubMed ID: 31889669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effects of neoadjuvant chemotherapy on the prognostic mortality risk of invasive transitional bladder cancer: a meta-analysis].
    Fan B; Zhang L; Li XC; Song YS; Guo EZ; Pan T; Shen L; Xin SY; Song XS; Wang JB
    Zhonghua Yi Xue Za Zhi; 2013 Jun; 93(22):1705-10. PubMed ID: 24124676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of Complete Pathologic Response (pT0) to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Carcinoma.
    Pokuri VK; Syed JR; Yang Z; Field EP; Cyriac S; Pili R; Levine EG; Azabdaftari G; Trump DL; Guru K; George S
    Clin Genitourin Cancer; 2016 Feb; 14(1):e59-65. PubMed ID: 26508364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of the outcomes of neoadjuvant and adjuvant chemotherapy for clinical T2-T4aN0-N2M0 bladder cancer.
    Wosnitzer MS; Hruby GW; Murphy AM; Barlow LJ; Cordon-Cardo C; Mansukhani M; Petrylak DP; Benson MC; McKiernan JM
    Cancer; 2012 Jan; 118(2):358-64. PubMed ID: 21717438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant chemotherapy administration and time to cystectomy for muscle-invasive bladder cancer: An evaluation of transitions between academic and community settings.
    Rose TL; Deal AM; Basch E; Godley PA; Rathmell WK; Kim WY; Whang YE; Dunn MW; Wang A; Chen RC; Nielsen ME; Pruthi RS; Wallen EM; Woods ME; Smith AB; Milowsky MI
    Urol Oncol; 2015 Sep; 33(9):386.e1-6. PubMed ID: 26122712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.